Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma
Status:
Completed
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to improve efficacy of treatment for patients with newly
diagnosed multiple myeloma who are not eligible for high-dose chemotherapy followed by
autologous stem cell transplantation by Bendamustin, Bortezomib (Velcade), and Prednisone.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital Heidelberg
Collaborators:
German Cancer Research Center inVentiv Health Clinical Janssen-Cilag International NV Mundipharma Research GmbH & Co KG